Green tea extract to prevent liver cancer in cirrhosis
Part of Cancer, Digestive system clinical trials.
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have been diagnosed with cirrhosis (scarring of the liver).
- Your liver is currently stable (no recent serious complications like fluid buildup or bleeding).
- You have never had liver cancer before.
- Your blood tests show your liver, kidneys, and blood cells are working well enough.
- You are able to care for yourself (score of 70 or higher on a daily activity scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies erlotinib, a medication used to block a growth signal, to see if it can prevent liver cancer in people with advanced liver scarring (cirrhosis or advanced fibrosis) who have never had liver cancer. It’s designed for adults with certain risk scores and good health function.
This trial tests whether taking low-dose aspirin can help prevent liver cancer in people with cirrhosis (scarring of the liver). Cirrhosis makes the liver more likely to develop cancer, and aspirin might reduce that risk.
This study looks at how a single session of endurance exercise (like walking or cycling) affects certain proteins in people with liver cancer. It may help researchers understand how exercise could support cancer treatment.
This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Hear when a new Cirrhosis, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.